Vaxigrip
Vaxigrip: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Drug interactions
- 11. Analogs
- 12. Terms and conditions of storage
- 13. Terms of dispensing from pharmacies
- 14. Reviews
- 15. Price in pharmacies
Latin name: Vaxigrip
ATX code: J07BB01
Active ingredient: inactivated split gravedo virus
Producer: Sanofi Pasteur S. A. (France)
Description and photo update: 2019-16-08
Vaxigrip is a vaccine for the prevention of influenza, which forms the development of specific immunity (lasting from 6 to 12 months) to epidemically relevant strains of influenza A and B.
Release form and composition
The dosage form of Vaxigrip is a suspension for intramuscular and subcutaneous administration, a slightly whitish, slightly opalescent liquid. Produced by:
- 0.5 ml of vaccine in a syringe, 1 syringe in a sealed cell package, in a cardboard box 1 package;
- 0.5 ml of vaccine in an ampoule, 10 ampoules in a blister, in a cardboard box, 2 packs (20 ampoules);
- 1 dose of vaccine (0.25 ml) in a syringe, 1 syringe in a sealed cell package, in a cardboard box 1 package;
- 5 ml bottle (bottle), 1 pc. in a cardboard box.
1 dose (0.5 / 0.25 ml) contains active substances - hemagglutinin and neuraminidase of the following viral strains:
- A (H1 N1) - 15 / 7.5 μg HA;
- A (H3 N2) - 15 / 7.5 μg HA;
- B - 15 / 7.5 μg HA.
Excipients: buffer solution (sodium chloride, sodium hydrogen phosphate dihydrate, potassium chloride, potassium dihydrogen phosphate, water for injection) - up to 0.5 ml.
Pharmacological properties
Vaxigrip promotes the formation of high specific tissue and humoral immunity against influenza (strengthening of the body's defenses in a collision with epidemically relevant strains of influenza A and B viruses included in this vaccine) in 80–95% of patients.
Antiviral antibodies, as a rule, are produced 10-15 days after vaccination, and immunity lasts for 6-12 months.
Pharmacodynamics
The features of the pharmacodynamics of the drug are not well understood.
Pharmacokinetics
Detailed studies of the pharmacokinetic characteristics of Vaxigrip have not been conducted.
Indications for use
According to the instructions, Vaxigrip is used to prevent influenza in adults and children over 6 months old. Vaccination is allowed for the following diseases / conditions:
- Diabetes;
- Chronic renal failure
- Diseases of the cardiovascular system and respiratory system;
- Immunodeficiency (including HIV infection);
- Malignant blood diseases;
- Concomitant therapy with cytostatics, immunosuppressants, high doses of glucocorticosteroids;
- Radiation therapy.
Vaxigrip can be used in the elderly (over 65) and pregnant women in case of a high risk of influenza infection.
Contraindications
- Acute fever or exacerbation of chronic diseases (vaccination can be carried out after remission or recovery);
- Allergic reactions to previous use of the drug;
- Mild ARVI (vaccination can be carried out after normalization of body temperature);
- Hypersensitivity to the components of the drug, incl. to aminoglycosides and chicken protein.
The decision to vaccinate pregnant women should be made by the doctor individually, taking into account the risk of illness and possible complications of influenza infection. It is safest to vaccinate in the II-III trimesters of pregnancy.
The use of Vaxigrip during breastfeeding is possible, since the drug has no toxic and teratogenic effect on the fetus.
Instructions for the use of Vaksigrip: method and dosage
The Vaxigrip vaccine can be administered:
- Subcutaneously deep into the upper third of the outer surface of the shoulder;
- Intramuscularly into the deltoid muscle;
- In the anterolateral thigh - young children.
Children from 6 months to 3 years old are injected once 0.25 ml of the drug; those who have not been vaccinated or who have not had the flu before, the vaccine is administered twice with an interval of 4 weeks.
For adults and children from 3 years old, Vaxigrip is administered once, 0.5 ml.
Patients with immunodeficiency may be given two doses of the drug, 0.25 ml each, with an interval of 4 weeks.
Side effects
- Often - sweating, fatigue, headache, malaise, hyperthermia, tremors, pain in the joints and muscles, neuralgia (transiently, disappear in 1-2 days);
- Rarely - paresthesia, thrombocytopenia, neuritis, encephalomyelitis, convulsions, Guillain-Barré syndrome (a clear connection with vaccination has not been established);
- Very rarely - allergic reactions up to shock, vasculitis with transient renal dysfunction.
Of the local reactions, the most likely: hyperemia, induration, soreness and edema at the injection site, ecchymosis.
Overdose
Information about Vaxigrip overdose is not provided by the manufacturer.
special instructions
Vaccination is carried out annually in the autumn-winter period. Its implementation is possible at the beginning of the epidemic rise in the incidence of influenza.
Intravenous administration of Vaxigrip is not allowed.
With mild ARVI and acute intestinal diseases, vaccination can be carried out after the body temperature has returned to normal.
On the day of vaccination, patients should be examined by a doctor (paramedic). Vaccination is not carried out at a body temperature above 37 ° C.
After using Vaxigrip with enzyme immunoassay, false positive results of serological tests are possible, which is due to the production of IgM.
Vaccination rooms should contain drugs for anti-shock treatment (epinephrine, glucocorticosteroids, etc.).
Vaxigrip vaccine may contain trace amounts of gentamicin.
Vaccination does not affect the speed of the psychomotor reaction and the ability to concentrate.
After immunization, the patient should be monitored by a health worker for half an hour.
The vaccination procedure and the opening of the ampoules is carried out with strict adherence to the rules of antiseptics and asepsis. The drug cannot be stored in an opened ampoule.
A drug with a broken labeling or ampoule integrity, stored in violation of the requirements, with altered physical properties (transparency, color) and with an expired shelf life is not suitable for use.
Application during pregnancy and lactation
The results of studies on the use of the vaccine in pregnant women confirm the absence of a negative effect of vaccination on the fetus and the body of the expectant mother. The presence of embryotoxic and teratogenic effects has not been proven. The decision to vaccinate a pregnant woman is made on an individual basis exclusively by a specialist who takes into account the risk of contracting the flu and the possible complications of this infectious disease. It is preferable to introduce Vaxigrip in the II ‒ III trimesters of pregnancy. If a pregnant woman is at an increased risk of developing serious post-influenza complications, the vaccine is recommended at any stage of pregnancy.
Vaccination during lactation is allowed.
Drug interactions
Vaxigrip can be used simultaneously with other inactivated vaccines, while contraindications to each of them must be taken into account (drugs should be injected with different syringes in different parts of the body).
Immunosuppressants and glucocorticosteroids lower the immune response to drug administration.
Analogs
Analogs of Vaxigrip are: Agrippal S1, Begrivac, Influenza vaccine inactivated eluate centrifuge, Pandeflu.
Terms and conditions of storage
Store in a dark place, out of reach of children, at a temperature of 2-8 ° C. Do not freeze.
The shelf life is 12 months.
Terms of dispensing from pharmacies
It is used only in medical institutions.
Reviews about Vaxigrip
Numerous reviews about Vaxigrip are mostly positive. Patients note the acceptable cost of the vaccine and effective protection against influenza after its administration, which in most cases is painless. The drug is not capable of provoking the flu. It is recommended to be administered to children and elderly people (over 65). However, Vaxigrip will not protect against ARVI, as well as in the event of an influenza pandemic.
The vaccine has a minimum of contraindications, so many patients are vaccinated not only for themselves, but for the whole family. In some cases, minor side effects have been reported, including fever, headache, sore throat and sore throat, but these resolve quickly. In general, the vaccine is well tolerated and often provides protection against infection for at least 12 months.
Price for Vaxigrip in pharmacies
The approximate price for Vaxigrip in pharmacy chains is 298–317 rubles (per 1 dose).
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
